Colchicine for Coronary Artery Disease: A Review

Tao Chen¹, Guihong Liu² and Bo Yu*¹

¹ Department of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, China, ² Department of Oncology, West China Hospital, Sichuan University, Chengdu, China

Coronary artery disease is a serious threat to human health. More and more evidences indicate chronic inflammatory plays a key role in the development of this disease. Inflammation markers are gradually used in the diagnosis and treatment. Although the treatment of coronary heart disease with colchicine is still controversial, more and more studies showed that patients can benefit from this medicine. In this review, we discuss and summarize colchicine on essential pharmacology, anti-inflammatory mechanism of action, and the most important and recent clinical studies. According to these literatures, colchicine possibly will possibly become a new valuable and cheap medicine for the treatment of coronary artery disease.

Keywords: colchicine, inflammation, coronary artery disease, percutaneous coronary intervention, coronary artery bypass grafting

INTRODUCTION

Coronary artery disease (CAD) is a pathological process characterized by the accumulation of atherosclerotic plaques in epicardial arteries (1, 2). Lifestyle adjustment, drug therapy, and invasive therapy can change this process. Despite the availability of safe and effective low-density lipoprotein (LDL)-lowering therapy and antiplatelet therapy, the incidence of cardiovascular disease has been increasing (3). In recent viewpoint, arteriosclerosis is not only caused by lipid accumulation but also a chronic inflammatory reaction. Some studies showed that more than 50% of cardiovascular events may be attributed partly to inflammation (4–6). The recent consensus published by the European Society of Cardiology (ESC) confirmed that inflammation is an important factor in atherosclerosis (2). The CANTOS study was the first large-scale clinical study to confirm that anti-inflammatory treatment could reduce cardiovascular events, providing definite evidence for the inflammation hypothesis of arteriosclerosis with a reduction from baseline in interleukin (IL)-6 (Figure 1). But canakinumab is limited in the cardiovascular field because of its high price and causing serious infections (7). However, the CIRT study showed methotrexate did not decrease the level of IL-1β, IL-6, or C reactive protein (CRP) and did not reduce cardiovascular events (8). Colchicine, one of the oldest drugs, is widely used for acute gout, familial mediterranean fever, and pericarditis, Behcet's disease (9). Over the past decades, with advances in the knowledge of cytoskeletal microtubules (MT) and anti-inflammatory effects of colchicine, low-dose colchicine (0.5–1.0 mg/daily) was increasingly administered for the therapy of cardiovascular diseases such as CAD, postoperative atrial fibrillation (in cardiac surgery), cardiac hypertrophy-associated heart failure (10). What's more, in an animal experiment, colchicine improved left ventricular (LV) function in coxsackievirus 3 (CVB3) induced myocarditis and decreased cardiac and splenic family pyrin domain-containing protein 3 (NLRP3) inflammasome activity (11). A large number of studies about colchicine make progress in the treatment of CAD (Table 1). The aim of this review is...
Colchicine is an alkaloid with the formula C22H25NO6. Pharmacological studies have shown that colchicine preferentially binds to three proteins, including tubulin, cytochrome p3a4 (CYP3A4), and P-glycoprotein (13). The tubulin prevents persistently the fusion of autophagic vacuoles with lysosomes in neurons, bone marrow, and muscle, resulting in the risk of damage to these organ systems, especially in patients with liver and/or renal insufficiency. CYP3A4 and P-glycoprotein largely contribute to affecting colchicine metabolism and colchicine's drug-drug interactions. CYP3A4 exists in hepatocytes and intestinal cells and metabolizes colchicine to 2- and 3-desmethylcolchicine. P-glycoprotein is an ATPase efflux pump, which exists in intestinal cells, liver cells, kidney cells, and the blood-brain barrier; it can affect the absorption of colchicine from the gastrointestinal tract. The prescribed dose, kidney or liver disease, and nature of adjunctive medication can trigger the risk of severe drug-drug interactions of colchicine. The combination with P-glycoprotein inhibitors (e.g., cyclosporine, calcium channel blockers, and ranolazine) or CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, fluoxetine, ketoconazole, nefazodone, and cimetidine) makes colchicine metabolism disorders, further leads to concentration of colchicine increase, and finally happens drug poisoning (13, 14).

**Anti-inflammatory Mechanisms of Action**

Colchicine was originally extracted from the autumn crocus as an anti-inflammatory drug and used by the ancient Greeks and Egyptians (15–17). The anti-inflammatory mechanism of colchicine mainly includes the following aspects. (1) Colchicine binds with high affinity to the specific domain of β-tubulin, resulting in (i) inhibition of tubulin assembly into MT, (ii) disassembly of preformed MT, and/or (iii) inhibition of membrane-bound tubulin sensitive cellular processes (10, 18). Through the mechanisms, different functions of MT are impaired such as amoeboid movements of leucocytes, exocytosis, and phagocytosis, separation of chromosome pairs during mitosis (19). Smooth muscle cells (SMC) secretion and other cellular atherogenic phenomena can be inhibited by colchicine through its anti-microtubule effect (18, 20), and multiple inflammatory factors are down-regulated by the effect of MT (17). (2) Colchicine can suppress NLRP3 inflammasome being present in myeloid cells (Figure 2), including monocytes, neutrophils, and eosinophils or its downstream inflammatory cytokine activation (21). Highly mature inflammatory cytokines IL-1β and IL-18 produced from NLRP3 lead to the progression of atherosclerotic plaques and even shedding of plaques (22, 23). In a large number of trials, NLRP3 expression and downstream cytokines in CAD were significantly higher compared with normal controls (24, 25). Blocking NLRP3 inflammasome not only inhibits oxidized LDL and cholesterol crystal-induced foam cell formation (26) but also has a good influence on ischemia/reperfusion injury, bringing about smaller infarct size and less fibrosis in mice (27). (3) High-sensitivity C-reactive protein (hs-CRP) as a downstream important effector of NLRP3 inflammasome is produced in hepatic through regulation by interleukin 6 (IL-6) (28). Colchicine can decrease significantly hs-CRP which is closely related to arteriosclerosis (29, 30). In the CANTOS study, the reduction of hs-CRP in the treatment group obviously increased cardiovascular benefits and reduced cardiovascular and total mortality (7). Nidorf et al. demonstrated that colchicine can...
**TABLE 1** A summary of important clinical studies about colchicine in coronary artery disease.

| Study | Study design | Sample size | Clinical setting | Colchicine dose | Median follow up | Main results |
|-------|--------------|-------------|------------------|-----------------|-----------------|-------------|
| **WITH GOUT** | | | | | | |
| Solomon et al. (38) | Retrospective cohort study | 1002 (501/501) | Patients with gout | — | 16.5 months | Reduced incidence of composite of MI, stroke, TIA adjusted HR 0.51 (95% CI: 0.30–0.88); P = 0.018 and all-caused mortality (adjusted HR 0.27 95% CI: 0.17–0.43) |
| Crittenden et al. (39) | Retrospective cohort study | 1288 (576/712) | Patients with gout | — | — | Reduced incidence MI (RR 0.46 P = 0.03) No significant change in mortality (P = 0.18) |
| **CCS** | | | | | | |
| LoDoCo trial (40) | RCT | 532 (282/250) | CCS | 0.5 mg daily | 36 months | Reduced incidence of CV death, non-cardioembolic stroke, ACS and out-of-hospital cardiac arrest (HR 0.33 95% CI: 0.18–0.59) |
| LoDoCo2 trial (41) | RCT | 5522 (2762/2760) | CCS | 0.5 mg daily | 28.6 months | Reduced incidence of CV death, myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization (HR 0.69 95% CI: 0.57–0.83) |
| **ACS** | | | | | | |
| Deftereos et al. (48) | RCT | 151 (77/74) | STMI | Loading dose of 2 mg and continuing with 0.5 mg twice daily | — | CK-MB AUC nearly half than the placebo group (p < 0.001). Smaller indexed CMR-defined MI size in the colchicine group (18.3 vs. 23.2 mL/1.73 m2, p = 0.019). Smaller relative MI size as a proportion of LV myocardial volume in the colchicine group (13.0% vs. 19.8%, p = 0.034). |
| CCS | | | | | | |
| COLCOT trial (49) | RCT | 4745 (2366/2379) | MI (<1 month) | Colchicine 0.5 mg daily | 22.6 months | Reduced incidence of CV death, cardiac arrest, myocardial infarction, stroke, or urgent hospitalizations for angina (HR 0.77 95% CI: 0.61–0.96) |
| COPS trial (50) | RCT | 795 (396/399) | ACS | 0.5 mg twice daily for the first month, then 0.5 mg daily for 11 months | 12 months | The primary outcome of all-cause mortality, ACS, ischemia-driven urgent revascularization, and non-cardioembolic ischemic stroke did not differ between colchicine and placebo 24 vs. 38 events (P = 0.09) |
| **PCI** | | | | | | |
| O’Keefe et al. (51) | RCT | 197 (130/67) | Patients undergoing PCI | 0.6 mg twice daily | 6 months | Sessions had restenosis to 47% lumen diameter narrowing in the placebo-treated group compared with 46% in the colchicine-treated group (p = NS) |
| Deftereos et al. (35) | RCT | 196 (100/96) | Patients undergoing PCI | 0.5 mg twice daily | 6 months | Stent restenosis rate was 16% in the colchicine group compared with 33% in the control group (OR: 0.38, 95% CI: 0.18–0.79, p = 0.007) |
| COLCHICINE-PCI trail (52) | RCT | 400 (206/194) | Patients undergoing PCI (50% ACS patients) | 1.2 mg 1–2 h pre-procedure followed by 0.6 mg 1 h later or immediately preprocedure | 30 days | The primary outcome of PCI-related myocardial injury did not differ between colchicine and placebo groups (67.3% vs. 64.2%, P = 0.19) |

**Effectively decrease hs-CRP in patients with chronic coronary syndrome (CCS)** (31). Measurement of hs-CRP has been shown to independently predict future cardiovascular events in patients with CCS (32), and those with acute coronary syndrome (ACS) (33). (4) Expression of surface markers of platelet activity can be reduced and leukocyte-platelet aggregation can be inhibited by colchicine, which is a major contributor to atherothrombosis (34). Recent data showed that colchicine has antiplatelet...
FIGURE 2 | A simplified approach to inflammasome activation pathways includes therapy mechanisms of colchicine and canakinumab. Colchicine affects the NLRP3 inflammasome by inhibiting the function of microtubules, further resulting decrease in the downstream inflammatory factors include IL-1β, IL-6, and HS-CRP. Canakinumab prevents IL-1β and further reduces the release of IL-6 from various types of cells. hs-CRP is produced in hepatic through regulation by IL-6. ASC, apoptosis-associated speck-like protein containing a CARD; NLRP3, NLR family pyrin domain containing 3; IL, interleukin; hs-CRP, High-sensitivity C-reactive protein.

activity (35, 36). (5) Colchicine treatment significantly reduces the expression of key inflammatory-related miRNA (37). (6) Colchicine also affects endothelial function (17). Colchicine improves endothelial function through its anti-inflammatory effect in CAD patients with leukocyte activation and reduces the adhesion of leukocytes to endothelium (16, 29). (7) In addition, the synthesis of prostaglandin E2, leukotriene B4, TNF-A, and TxA2, as well as the activity of COX-2 can be inhibited by Colchicine. Even at low doses, it inhibits inflammation by reducing the expression of E and P-selectin and weakens the adhesion of polymorphonuclear neutrophils (PMN) to the endothelium and inhibits neutrophil migration (16, 17).

RESEARCH PROGRESS OF COLCHICINE IN THE TREATMENT OF CORONARY ARTERY DISEASE

Chronic Coronary Syndromes
Chronic coronary syndrome is usually characterized by a reversible myocardial supply-demand mismatch. It is associated with ischemia or hypoxia, usually induced by exercise, emotion, or other stress, and occasionally occurs spontaneously (2). Despite routine treatment with antiplatelet and statins, patients are still at high risk for cardiovascular events. These treatments do not interfere with inflammation. A retrospective study matched 501 users of colchicine for gout with an equal number of non-users for a median follow-up of 16.5 months. Cardiovascular (CV) events occurred in 28 patients of 501 (5.6%) who received colchicine and 82 patients of 501 (16.4%) assigned no colchicine (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.30–0.88, \( p = 0.016 \)) and a 73% reduction in all-cause mortality (HR 0.55, 95% CI: 0.35–0.85, \( p = 0.007 \)) (38). Another retrospective study included 1288 gout patients, which were divided into Colchicine (876) group and no colchicine (712) group. Prevalence of (myocardial infarction) MI occurred in 1.2% of patients who received colchicine and 2.6% of patients assigned no colchicine (relative risk [RR]:0.46, \( p = 0.03 \)). Fewer deaths and lower CRP levels appeared in the colchicine group, although without statistical significance (39). The LoDoCo trial showed that low-dose colchicine reduced the risk of plaque instability, thereby improving clinical outcomes in patients with CCS. The primary outcome was observed in 15 patients of 282 (5.3%) among users and 40 patients of 501 (16.0%) assigned among non-users (HR: 0.33; 95% CI: 0.18–0.59, \( p = 0.001 \)). A low dose of colchicine in combination with other standard secondary
prevention therapies occurred the prevention of cardiovascular events for patients with CCS (40). Recently, the LoDoCo2 study, published in the New England Journal, further confirmed the role of colchicine in the treatment of CCS, which matched 2762 users with 2760 non-users for a median of 28.6 months. The primary outcome which included cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization occurred in 187 patients (5.3%) who received colchicine and 264 patients (9.6%) who did not receive colchicine (HR, 0.69; 95% CI: 0.57–0.83, P < 0.001). A key secondary endpoint event occurred in 115 patients (4.2%) who received colchicine and 157 patients (5.7%) assigned no colchicine (HR, 0.72; 95% CI: 0.57–0.92, P = 0.007). Secondary endpoints were tested in a hierarchical manner. Notably, the incidence of death from non-cardiovascular was higher in the colchicine group than placebo group (incidence, 0.7 vs. 0.5 events/100 person-years; HR, 1.51; 95% CI: 0.99–2.31) (41). Both LoDoCo and LoDoCo2 include a large number of patients, Colchicine can be an important supplement for secondary prevention of CCS. Some meta-analyses have shown that the reduction of inflammatory factors and plaque stabilization can be achieved by oral colchicine (42, 43). In general, many trials have confirmed the effectiveness of colchicine in patients with CCS. The ongoing DRC-04 study will demonstrate the effectiveness and safety of colchicine on patients with diabetes mellitus type 2 (T2DM) and CCS (Table 2).

**Acute Coronary Syndrome**

Acute coronary syndrome was defined as symptoms of acute myocardial ischemia associated with either elevated troponin or ECG changes. The current treatments for ACS mainly include antiplatelet, anticoagulation, blood lipid regulation, and operations, such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) (44, 45). Even with the above treatments, mortality and morbidity in patients with ACS still keep increasing. Inflammation is involved in all stages of atherosclerosis, including plaque formation, progression, instability, and rupture. Anti-inflammatory treatment may be an effective breakthrough for ACS. In an animal trial, Colchicine can significantly reduce infarct area and cardiac fibrosis in mice, and improve hemodynamic parameters (46). Another animal trial showed the anti-inflammatory mechanism of colchicine can protect the myocardium in the rat MI model (47). In the above studies, a unique dose of colchicine by limitation of the inflammation at the early stage of MI decreased myocardial injuries, which was manifested as a reduction in infarct size and T troponin level at 24 h. More importantly, colchicine improved long-term cardiac remodeling by improving hemodynamic parameters and reducing myocardial fibrosis (46, 47). These animal studies provide some evidences for colchicine treatment of ACS. Deftereos et al. have demonstrated in a double-blind that a 5-day course of treatment combined with colchicine and PCI led to a reduction in infarct size in 151 patients with STEMI (48). In this trial, Colchicine significantly decreased circulating levels of CK-MB, troponin measured 72 h post-MI, and infarction volume measured using cardiac MRI compared to placebo (48). The COLCOT clinical trial including 4745 patients followed for a median of 22.6 months. The primary endpoint including death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization occurred in 5.5% of the patients who received colchicine, as compared with 7.1% in the placebo group (HR, 0.77; 95% CI: 0.61–0.96, P = 0.02). The hazard ratios were 0.84 (95% CI: 0.46–1.52) for death from cardiovascular causes, 0.83 (95% CI: 0.25–2.73) for resuscitated cardiac arrest, 0.91 (95% CI: 0.68–1.21) for myocardial infarction, 0.26 (95% CI: 0.10–0.70) for stroke, and 0.50 (95% CI: 0.31–0.81) for urgent hospitalization for angina leading to coronary revascularization. The result showed the primary end point, stroke, urgent hospitalization for angina leading to coronary revascularization was significant lower in the colchicine group compared with the placebo group (49). The COPS randomized clinical trial recruited a total of 795 patients with ACS, 396 in colchicine group and 399 in the placebo group at 1 year of follow-up. The result showed that standard treatment with colchicine had no significant effect on cardiovascular outcomes and occurred a higher rate of mortality, such as 24 events in the colchicine group and 38 events in the placebo group (P = 0.09, log-rank). The rate of total death in the colchicine group was higher (8 versus 1; P = 0.017 log-rank), particularly, non-cardiovascular death in the colchicine group (5 versus 0; P = 0.024 log-rank). However, if the composite endpoint used only cardiovascular death rather than total death (cardiovascular death, stroke, ACS, and urgent revascularization) over the 12-month follow-up, the group of colchicine had a lower event rate (5.0% versus 9.5%; HR, 0.51 [95% CI: 0.29–0.89], P = 0.019). What’s more, at 400 days, there was a statistically significant difference between groups for the primary outcome (ACS, stroke, death, and urgent revascularization), with 24 events in the colchicine group compared with 41 events in the placebo group (P = 0.047, log-rank test) (50). Although COPS had negative results during 12 months of follow-up, we need to take into account the limitations of this trial, such as the insufficient sample size, low proportion of women, and limited follow-up time. When making a further analysis, firstly, the dose of colchicine was high in the COPS trial during the first month, and negative results may be caused by this factor. Secondly, the primary outcome at 12 months and 400 days were contradictory. It cannot be ruled out that the benefit further increases as the duration of colchicine administration is prolonged. Therefore, colchicine in the treatment of ACS is worth long-term observation. Although colchicine does not get consistent results in the treatment of ACS, many trials have been added to confirm the treatment of ACS with colchicine. We will see the results of more clinical studies about ACS in the future, including COACS, COCOMO-ACS, COLCARDIO-ACS, CADENCE, COLD-MI, COLOCT, etc.

**Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting**

Percutaneous coronary intervention is the most important way to treat CAD. The processes of PCI including wire injury, microdissections at the site of balloon inflations, and vascular trauma due to high-pressure balloon inflations can further
| Study                      | NCT No.       | Study design | Clinical condition | Target number | Interventions                  | Primary outcome measures                                                                 |
|---------------------------|---------------|--------------|--------------------|---------------|--------------------------------|------------------------------------------------------------------------------------------|
| **CCS**                   |               |              |                    |               |                                |                                                                                          |
| DRC-04                    | NCT03376698   | RCT, Phase 2 | T2DM with CAD      | 69            | Colchicine 0.5 or 0.25 mg daily vs. placebo | Change in serum hs-CRP                                                                   |
| **ACS**                   |               |              |                    |               |                                |                                                                                          |
| COACS                     | NCT01906749   | RCT, Phase 4 | ACS                | 500           | Colchicine 0.5 mg daily vs. placebo | Overall mortality, new acute coronary syndrome, and ischemic stroke                      |
| COCOMO-ACS                | ANZCTR reg no: ACTRN1261800 0809235 | RCT, Phase 2 | ACS                | 82            | Colchicine 0.5 mg daily vs. placebo | Coronary plaque minimum brous cap thickness on OCT at 12 months                          |
| COLCARDIO-ACS             | ANZCTR reg no: ACTRN1261600 0400460 | RCT, Phase 3 | ACS with hs-CRP 2 mg/L | 300          | Colchicine 0.5 mg daily vs. placebo | Composite MACE (CV death, ACS, urgent revascularisation, non- fatal stroke) at a median follow-up of 3 years |
| Effect of Colchicine in Patients With Myocardial Infarction | NCT04218786 | RCT, Phase 2 | STEMI              | 800           | Colchicine 0.5mg daily vs. placebo  | Cardiovascular death Non-fatal myocardial infarction Resuscitated cardiac arrest Hospitalization for unstable angina |
| **CADENCE**               | NCT04181906   | RCT, Phase 3 | T2DM or pre-diabetes and a recent Non-STEMI, STEMI, stroke or TIA | 115 | Colchicine 0.6mg daily vs. placebo | 6 month change in FDG uptake TBR in the MDS                                                  |
| **COLD-MI**               | NCT04420624   | RCT, Phase 2,3 | MI                 | 54            | Colchicine 1 or 0.5 mg daily vs. placebo | Percentage of myocardial denervation                                                      |
| **COLOCT**                | NCT04848857   | RCT, Phase 4 | ACS                | 128           | Colchicine 0.5 mg daily vs. placebo | Changes of the thickness of fibrous cap of coronary artery plaque measured by OCT        |
| CLEAR SYNERGY Neutrophil Substudy | NCT03874338 | A sub study of multicenter 2 × 2 randomized placebo controlled trial | STEMI           | 670 | Colchicine vs. placebo | Change in soluble L-selectin between baseline and 3 months after STEMI                     |
| Post-MI PET Scan Imaging of Inflammation | NCT02281305 | RCT, Phase 4 | MI                 | 20            | Colchicine 2 mg loading dose; 0.5 mg bid for 5 days vs. placebo | Degree of inflammation of the involved myocardium as assessed by the PET scan             |
| **PCI**                   |               |              |                    |               |                                |                                                                                          |
| COVERT-MI                 | NCT03156816   | RCT, Phase 2 | STEMI with PCI     | 194           | Bolus colchicine 2 mg then 0.5 mg BD for 5 days vs. placebo | Infarct size (% of LV mass) on CMR                                                       |
| CLEAR SYNERGY             | NCT03048825   | RCT, 2 × 2 factorial (with Spironolactone) | MI with PCI     | 7000          | Colchicine 1 mg daily or spironolactone 25 mg daily vs. placebo | Composite of MACE (death, recurrent target vessel MI, stroke, or ischemia driven target vessel revascularization) Composite of cardiovascular death, recurrent myocardial infarction, or stroke Composite of cardiovascular death or new or worsening heart failure |
| ORCA                     | NCT04382443   | RCT, Phase 4 | PCI                | 450           | BMS + Colchicine (0.5 mg twice a day during the first 3 months after stent implantation) vs. DES | Composite of death, MI and ischemic TVR death included cardiac, non-cardiac and non-determined |

(Continued)
TABLE 2 (Continued)

| Study | NCT No. | Study design | Clinical condition | Target number | Interventions | Primary outcome measures |
|-------|---------|--------------|--------------------|---------------|---------------|-------------------------|
| Colchicine in Periprocedural Myocardial Infarction: the Role of Alpha Defensin | NCT03735134 | Non-Randomized. Not Applicable | MI with PCI | 180 | Colchicine vs. placebo | Occurrence of periprocedural myocardial infarction post elective PCI |
| Anti-inflammatory Effects of Colchicine in PCI (a substudy of the COLCHICINE-PCI trial) cerebrovascular disease and PAD | NCT01709981 | RCT, Phase 4 | PCI | 280 | 1.2 mg colchicine 1–2 h prior PCI, followed by 0.6 mg 1 hour later vs. placebo | Percent change in post-procedural IL-6 concentration from baseline to 30 min–1 h after PCI |
| CONVince | NCT02898610 | RCT, Phase 3 | Ischemic attack, Transient stroke | 2623 | Colchicine 0.5 mg daily vs. placebo | Recurrence of non-fatal ischemic stroke (Any recurrence of non-fatal ischemic stroke) On-fatal major cardiac event (Non-fatal hospitalization for unstable angina, myocardial infarction, cardiac arrest) Vascular death (Fatal ischemic stroke, myocardial infarction, cardiac arrest) |
| LEADER-PAD | NCT04774159 | RCT, Phase 3 | Peripheral arterial disease | 150 | Colchicine 0.5 mg daily vs. placebo | Efficacy outcomes: major adverse cardiovascular and limb events Safety outcomes: gastrointestinal toxicity that leads to treatment interruption or discontinuation, infection (e.g., pneumonia) and incident cancer |

RCT, randomized controlled trial; T2DM, diabetes mellitus type 2; CAD, coronary artery disease; hs-CRP, high-sensitivity C-reactive protein; ACS, acute coronary syndrome; OCT, optical coherence tomography; CV, cardiovascular; MACE, major adverse cardiac events; STEMI, ST-elevation myocardial infarction; non-STEMI, non-ST-elevation myocardial infarction; TIA, transient ischemic attack; FDG, fluorodeoxyglucose; TBR, tissue to blood ratio; MDS, maximum disease segment; MI, myocardial infarction; PET, positron emission tomography; CMR, cardiovascular magnetic resonance; PCI, percutaneous coronary intervention; BMS, bare metal stents; DES, drug eluting stent; TVR, target vessel revascularization; IL-6, interleukin-6.

aggravate plaque instability and inflammation (2, 44). Therefore, many scholars take special attention to the curative effect of controlling inflammation on PCI patients. Early studies on colchicine mainly focused on stenosis after PCI. The first study on the use of colchicine in PCI patients was published in 1992, including 197 patents, which found that colchicine 0.6 mg BD did not reduce vascular stenosis (51). A prospective, randomized clinical trial published in 2013 included 196 diabetic patients who received bare-metal stents and proved patients who received a 6-month course of 0.5 mg BD with colchicine can benefit. The angiographic in-stent restenosis rate occurred in 16% of the patients who received colchicine and 33% of patients assigned no colchicine (odds ratio [OR]: 0.38, 95% CI: 0.18–0.79, \( p = 0.007 \)) (35). COLCHICINE-PCI randomized clinical trial recruited a total of 400 patients with 206 assigned to the colchicine group and 194 to the placebo group. The colchicine group was scheduled for acute preprocedural oral administration of colchicine, and the other group received an oral placebo. The composite outcome of death, non-fatal myocardial infarction, and target vessel revascularization at 30 days (11.7% versus 12.9%, \( P = 0.82 \)), and the outcome of PCI-related MI (2.9% versus 4.7%, \( P = 0.49 \)) did not differ between colchicine and placebo groups (52). There is very little information on the use of colchicine in CABG. Giannopoulos et al. demonstrated in a prospective, double-blind trial about CABG including 59 patients with 30 assigned to the colchicine group and 29 to the placebo group that treatment with colchicine led to a reduction in increases of hsTnT and CK-MB (53). In the trial, the median area under curve (AUC) for hsTnT was 20,363 pg h/ml (13,891–31,661) in the colchicine group versus 40,755 pg h/ml (20,868–79,176) in controls (\( p = 0.002 \)). AUC for CK-MB was 1,586 ng h/ml (1,159–2,073) in the and colchicine group 2,552 ng h/ml (1,564–4,791) in control (\( p = 0.003 \)). In general, a short perioperative colchicine administration can reduce the elevation of hsTnT and CK-MB compared with placebo (53). The result was partly attributed to the anti-inflammation of colchicine. At present, considering the number of trials and patients involved were too small, and the results were inconsistent, more trials are needed to take part. Ongoing clinical trials of colchicine in PCI include COVERT-MI, CLEAR-SYNERGY, ORCA, etc.
SAFETY AND ADVERSE REACTIONS

0.5–1.0 mg of colchicine per day has proven relatively safe, as evidenced in many studies. However, it is noteworthy that patients with severe kidney or hepatic disease have been expelled from most of these trials. If patients have severe renal or liver function damage, the safety of colchicine decreases and even causes fatal toxicity. The therapeutic window of colchicine is narrow (54). Colchicine is toxic at doses greater than 0.1 mg/kg and lethal at 0.8 mg/kg (13). A meta-analysis focusing on adverse events on colchicine for the treatment of cardiovascular diseases demonstrated the occurrence of adverse events with colchicine was reported in 15.3 vs. 13.9% of patients [RR 1.26, 95% CI: 0.96–1.64, P = 0.09] (55). However, most patients can tolerate a low dose of colchicine well over the long term. The most common colchicine-related adverse events are gastrointestinal discomforts including nausea, vomiting, diarrhea, and abdominal discomfort. Other adverse events include myotoxicity, hepatic event, hematology event, cutaneous event, and infectious event (54). In particular, colchicine may increase the incidence of pneumonia. In COLCOT trial, Pneumonia as a serious adverse event occurred in 0.9% of the patients who received colchicine and 0.4% of patients assigned no colchicine (P = 0.03) (49). In another study, which included 24,410 patients, the overall incidence rates of pneumonia in the colchicine group were 18.6 per 1,000 person-years as compared with 12.6 per 1,000 person-years in non-colchicine group. Pneumonia was higher in the colchicine group [adjusted HR, 1.42; 95% CI: 1.32–1.53; P < 0.05]. The risk of pneumonia is also closely related to the cumulative dose and duration of use (56). Increasing the rate of infection may be attributed to the suppression of immunity. In addition, the increase in non-cardiovascular death also deserves attention. The LoDoCo2, COPS have mentioned that colchicine may increase the rate of non-cardiovascular death. Attention should also be paid to the combination of colchicine and other drugs such as CYP3A4 inhibitors, P-glycoprotein inhibitors, or statins. When combined with drug CYP3A4 inhibitors or P-glycoprotein inhibitors, the concentration of colchicine is increased, which leads to an increase in adverse events. Combination use of statins increases with may increase the risk of myopathy (54). Although colchicine is relatively safe, considering its narrow therapeutic range and interactions with other drugs, we need to pay attention to its adverse reactions, especially in patients with impaired liver and kidney function. When considering the symptoms of an adverse reaction, the clinician first confirms whether the adverse reaction is caused by colchicine. Blood concentration monitoring can provide more scientific clues. Once established, dosage reduction or withdrawal should be actively considered.

DISCUSSION

At present, Anti-inflammatory treatment for CAD is getting more and more attention but there are also many controversies. This article will discuss the following aspects. Firstly, the author considers it is highly possible that colchicine in the treatment of CAD will be written into guidelines, but it is too early to draw a conclusion at present. The results of five trials (LoDoCo, LoDoCo2, Deftereos et al., COLCOT, Spyridon Deftereos et al.) were positive and two trials [JAMES H. O’KEEFE, et al., COLCHICINE-PCI trail] were negative. The result of the COPS trial was special, with a negative result at 12 months of follow-up and a positive result at 400 days of follow-up. When we further analyze, the weight of positive results is larger than negative. A meta-analysis including LoDoCo2, COPS, COLCOT, Spyridon Deftereos et al., and LoDoCo trials indicated that the risk of major adverse cardiovascular events (MACE) can be reduced by low-dose colchicine (57). Furtherly analyzing the grouping situation, the results of colchicine in CCS are relatively consistent. However, the results of ACS and PCI with colchicine are not consistent. Many reasons should be considered for this phenomenon. To begin with, compared with CCS, the treatment process of ACS and PCI is more complex, with higher risk and worse prognosis. What is more, many factors affect the prognosis of ACS and PCI, including the condition of patients, timeliness of the visit, quality of medication administration, and quality of the surgeon. Therefore, the weight of anti-inflammatory therapy in the whole process is relatively small, which may be an important reason for the inconsistent outcome. Because of these reasons, enthusiasm for colchicine in the treatment of ACS and PCI is growing. Secondly, inflammatory markers for assessing and treating CAD are unclear, unlike blood lipids, especially low-density lipoproteins, which can be used as indicators for monitoring the effectiveness of statins. Although many inflammatory indicators have been mentioned, such as hs-CRP, IL-1β, IL-18, and IL-6. White blood cell was even considered to be an independent predictor of MACE in a prospective study (58). But the sensitivity and specificity of these inflammation indicators are controversial. Among the inflammation biomarkers, hs-CRP is the most widely studied. In CANTOS study, the reduction of hs-CPR is parallel to the reduction in cardiovascular events (7). However, in COLCHICINE-PCI trial, colchicine could prevent a rise of hs-CRP during an acute injury, but which could not reduce PCI-related myocardial injury or 30-day major cardiovascular events (52). In the small subgroup of COLCOT trial, a large (>65%) reduction in the C-reactive protein level occurred over the first 6 months after myocardial infarction in colchicine and control groups, but the difference between the changes in the groups was not significant (49). At present, routine assessment of hs-CRP levels does not be advised as part of risk assessment for cardiovascular prevention by the European Society of Cardiology guidelines (59), while the American College of Cardiology guidelines suggest aggressive testing for hs-CRP levels (60). Inflammation indicators need more data to confirm. Finally, based on the common etiology and pathophysiological grounds of arteriosclerotic diseases, whether colchicine can prevent and treat cerebrovascular disease and peripheral arterial disease (PAD) is also worth looking forward to. A systematic review and meta-analysis including four randomized controlled trials (RCTs) and one retrospective cohort study confirmed that patients with stroke may benefit from colchicine (61). Unfortunately, clinical trials of colchicine for peripheral artery
is cheap and relatively safe. At the same time, we need to care about the adverse reactions and drug interactions, in particular, colchicine may be associated with increased rates of pneumonia and non-cardiovascular death. It is highly probable that the inhibition of inflammation will become the important cornerstone of CAD treatment.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

**FUNDING**

This study was supported by the Liaoning Province Central Guiding Local Science and Technology Foundation (No. 2019JH6/10400005) and the National Natural Science Foundation of China (No. 8217021483).

**REFERENCES**

1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberg ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* (2019) 74:e177–232.

2. Knuuti J, Wijna W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* (2020) 41:407–77.

3. Bohn A, Ur E. The obesity epidemic and its cardiovascular consequences. *Curr Opin Cardiol.* (2006) 21:353–60.

4. Moutafou Sherif HR, Niccoli G, Scalone G. TCT-599 Not all plaque ruptures are born equal: an optical coherence tomography study. *J Am Coll Cardiol.* (2016) 68:B243. doi: 10.1016/j.jacc.2016.02.108

5. Lawler PR, Bhatt DL, Godoy LC, Luscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. *Eur Heart J.* (2021) 42:2798–9. doi: 10.1093/eurheartj/ehab038

6. Bouabdallaoui N, Tardif JC. Initiation of low-dose colchicine early after myocardial infarction. *Eur Heart J.* (2021) 42:4113–31. doi: 10.1093/eurheartj/ehab099

7. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur Heart J.* (2018) 39:3499–507. doi: 10.1093/eurheartj/ehy310

8. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. *N Engl J Med.* (2019) 380:752–62. doi: 10.1056/NEJMoa1809798

9. Karamanou M, Tsoucalas G, Pantos K, Androutsos G. Isolating colchicine in 19th century: an old drug revisited. *Curr Pharm Des.* (2018) 24:654–8. doi: 10.2174/138161282466180115105850

10. Chaldakov GN. Colchicine, inflammation and fibrosis in cardiovascular disease- Merging three classical tales. *Biomed Rev.* (2017) 28:110–5. doi: 10.1016/j.berm.2017.03.002

11. Chaldakov GN. Colchicine, inflammation and fibrosis in cardiovascular disease- Atherosclerosis. *Atherosclerosis.* (1982) 44:385–90. doi: 10.1016/0021-9150(82)90013-2

12. Bhattacharyya B, Howard R, Maity SN, Brossi A, Sharma PN, Wolff J. B ring regulation of colchicine binding kinetics and fluorescence. *Proc Natl Acad Sci USA.* (1986) 83:2052–5. doi: 10.1073/pnas.83.7.2052

13. Niel E, Scherrmann JM. Colchicine today. *Joint Bone Spine.* (2006) 73:672–8.

14. Villa Zapata L, Hansten PD, Horn JR, Boyce RD, Gephart S, Subbian V, et al. Evidence of clinically meaningful drug-drug interaction with concomitant use of colchicine and clarithromycin. *Drug Saf.* (2020) 43:661–8. doi: 10.1007/s40264-020-00930-7

15. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. *Clin Ther.* (2014) 36:1465–79. doi: 10.1016/j.clinthera.2014.07.017

16. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. *J Clin Invest.* (1995) 96:994–1002. doi: 10.1172/JCI118147

17. Leung YY, Yao Hui LL, Kraus VB. Colchicine–Update on mechanisms of action and therapeutic uses. *Semin Arthritis Rheum.* (2015) 45:341–50. doi: 10.1016/j.semarthrit.2015.06.013

18. Chaldakov GN. Colchicine, inflammation and fibrosis in cardiovascular disease- Merging three classical tales. *Biomed Rev.* (2018) 28:110–5. doi: 10.1016/j.berm.2017.03.002

19. Molad Y. Update on colchicine and its mechanism of action. *Carr Rheumatol Rep.* (2002) 4:252–6. doi: 10.1002/sr.2007-3

20. Chaldakov GN. Antitubulins - A New Therapeutic Approach for Atherosclerosis?. *Atherosclerosis.* (1982) 44:385–90. doi: 10.1016/0021-9150(82)90013-2

21. Silvis MJM, Fiolet ATL, Opstal TSJ, Dekker M, Suquilanda D, Zivkovic M, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: a LoDoCoZ2 biomarker substudy. *Atherosclerosis.* (2021) 334:93–100. doi: 10.1016/j.atherosclerosis.2021.08.005

22. Grebe A, Hess F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. *Circ Res.* (2018) 122:1722–40. doi: 10.1161/CIRCRESAHA.118.311362

23. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. *Circulation.* (2001) 104:1598–603. doi: 10.1161/hc3901.1996721

24. Wang L, Qu P, Zhao Y, Wang H, Lou D, Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its
Chen et al. Colchicine a Review

43. Xiang Z, Yang J, Yang J, Zhang J, Fan Z, Yang C, et al. Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis. Intern Emerg Med. (2021) 16:487–96. doi: 10.1007/s11739-020-02606-7

44. Collet JP, Thiele H, Barabito E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. (2021) 42:1289–367.

45. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. (2018) 39:119–77. doi: 10.1093/eurheartj/ehx393

46. Akodad M, Faucconnier J, Sicard P, Huet F, Blandel F, Bourret A, et al. Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. J Intern Card. (2017) 240:347–53. doi: 10.1016/j.jicard.2017.03.126

47. Bakhta O, Blanchard S, Guilhot AL, Tamareille S, Mirebeau-Prunier D, Jeannin P, et al. Cardioprotective role of colchicine against inflammatory injury in a rat model of acute myocardial infarction. J Cardiovasc Pharmacol Ther. (2018) 23:446–55. doi: 10.1177/1074248418763611

48. Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. CIRCULATION. (2015) 132:1395–403. doi: 10.1161/CIRCULATIONAHA.115.017611

49. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. (2019) 381:2497–505. doi: 10.1056/NEJMoa192388

50. Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. (2020) 142:1890–900.

51. O’Keeffe JH, McCallister BD, Bateman TM, Kuhnelin DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. (1992) 19:1597–600. doi: 10.1016/0735-1097(92)00624-v

52. Shah R, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv. (2020) e1008717. doi: 10.1161/CIRCINTERVENTIONS.119.008717

53. Giannopoulos G, Angelidis C, Kouritas VK, Vedelias F, Filippatos G, Cleman MW, et al. Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting. Am J Cardiol. (2015) 115:1376–81. doi: 10.1016/j.amjcard.2015.02.036

54. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. (2010) 48:407–14. doi: 10.3109/15563650.2010.495348

55. Andreis A, Iamazio M, Avondo S, Casula M, Paneva E, Piroli F, et al. Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14 188 patients from 21 randomized controlled trials. J Cardiovasc Med. (2021) 22:637–44. doi: 10.2459/JCM.0000000000001157

56. Tsai TL, Wei JC, Wu YT, Ku YH, Lu KL, Wang YH, et al. The association between usage of colchicine and pneumonia: a nationwide, population-based cohort study. Front Pharmacol. (2019) 10:908. doi: 10.3389/fphar.2019.00908

57. Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. (2021) 42:2765–73. doi: 10.1093/eurheartj/ehab115

58. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White blood cell count and major adverse cardiovascular events after percutaneous coronary intervention in the contemporary era: insights from the PARIS study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. (2017) 10:e004981. doi: 10.1161/CIRCINTERVENTIONS.117.004981
59. Piepoli MF, Hoes AW, Agewall S, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). *Int J Behav Med.* (2017) 24:321–419.

60. Goff DC Jr., Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr., Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* (2014) 63:2935–59.

61. Khandkar C, Vaidya K, Patel S. Colchicine for stroke prevention: a systematic review and meta-analysis. *Clin Ther.* (2019) 41:582–90.e3.

62. Kelly P, Weimar C, Lemmens R, Murphy S, Purroy F, Arsovsk A, et al. Colchicine for prevention of vascular inflammation in non-cardioembolic stroke (CONVINCE) – study protocol for a randomised controlled trial. *Eur Stroke J.* (2021) 6:222–8. doi: 10.1177/2396987320972566

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chen, Liu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.